Literature DB >> 34297326

Exploring novel capping framework: high substituent pyridine-hydroxamic acid derivatives as potential antiproliferative agents.

Fernando Hernández-Borja1, Itzel Mercado-Sánchez1, Yolanda Alcaraz2, Marco A García-Revilla1, Clarisa Villegas Gómez1, David Ordaz-Rosado3, Nancy Santos-Martínez3, Rocío García-Becerra4, Miguel A Vazquez5.   

Abstract

PURPOSE: Histone deacetylases (HDACs) play a vital role in the epigenetic regulation of gene expression due to their overexpression in several cancer forms. Therefore, these enzymes are considered as a potential anticancer drug target. Different synthetic and natural structures have been studied as HDACs inhibitors; based on available structural design information, the capping group is important for the biological activity due to the different interactions in the active site entrance. The present study aimed to analyze high substituted pyridine as a capping group, which included carrying out the synthesis, antiproliferative activity analysis, and docking studies of these novel compounds.
METHODS: To achieve the synthesis of these derivatives, four reaction steps were performed, generating desired products 15a-k. Their effects on cell proliferation and gene expression of p21, cyclin D1, and p53 were determined using the sulphorhodamine B (SRB) method and quantitative real-time polymerase chain reaction. The HDAC1, HDAC6, and HDAC8 isoforms were used for performing docking experiments with our 15a-k products. RESULT: The products 15a-k were obtained in overall yields of 40-71%. Compounds 15j and 15k showed the highest antiproliferative activity in the breast (BT-474 and MDA-MB-231) and prostate (PC3) cancer cell lines at a concentration of 10 µM. These compounds increased p21 mRNA levels and decreased cyclin D1 and p53 gene expression. The docking study showed an increment in the strength, and in the number of interactions performed by the capping moiety of the tested molecules compared with SAHA; interactions displayed are mainly van der Waals, π-stacking, and hydrogen bond.
CONCLUSION: The synthesized compounds 2-thiophene (15j) and 2-furan (15k) pyridine displayed cell growth inhibition, regulation of genes related to cell cycle progression in highly metastatic cancer cell lines. The molecular coupling analysis performed with HDAC1, HDAC6 and HDAC8 showed an increment in the number of interactions performed by the capping moiety and consequently in the strength of the capping group interaction.
© 2021. Springer Nature Switzerland AG.

Entities:  

Keywords:  Antiproliferative compounds; Capping framework; Docking; Gene expression; HDACs; High substituent pyridine

Mesh:

Substances:

Year:  2021        PMID: 34297326      PMCID: PMC8602590          DOI: 10.1007/s40199-021-00406-8

Source DB:  PubMed          Journal:  Daru        ISSN: 1560-8115            Impact factor:   4.088


  53 in total

Review 1.  Chimeric HDAC inhibitors: Comprehensive review on the HDAC-based strategies developed to combat cancer.

Authors:  Heba M Hesham; Deena S Lasheen; Khaled A M Abouzid
Journal:  Med Res Rev       Date:  2018-05-07       Impact factor: 12.944

Review 2.  Epigenetic therapy of cancer with histone deacetylase inhibitors.

Authors:  K C Lakshmaiah; Linu A Jacob; S Aparna; D Lokanatha; Smitha C Saldanha
Journal:  J Cancer Res Ther       Date:  2014 Jul-Sep       Impact factor: 1.805

3.  Perfluorinated HDAC inhibitors as selective anticancer agents.

Authors:  James W Walton; Jasmine M Cross; Tina Riedel; Paul J Dyson
Journal:  Org Biomol Chem       Date:  2017-11-07       Impact factor: 3.876

Review 4.  Emerging role of histone deacetylase inhibitors as anti-breast-cancer agents.

Authors:  Meran Keshawa Ediriweera; Kamani Hemamala Tennekoon; Sameera Ranganath Samarakoon
Journal:  Drug Discov Today       Date:  2019-02-15       Impact factor: 7.851

5.  Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment.

Authors:  L Huang; A B Pardee
Journal:  Mol Med       Date:  2000-10       Impact factor: 6.354

6.  Synthesis, ex vivo and in silico studies of 3-cyano-2-pyridone derivatives with vasorelaxant activity.

Authors:  Fernando Hernández; Arturo Sánchez; Priscila Rendón-Vallejo; César Millán-Pacheco; Yolanda Alcaraz; Francisco Delgado; Miguel A Vázquez; Samuel Estrada-Soto
Journal:  Eur J Med Chem       Date:  2013-10-14       Impact factor: 6.514

7.  A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells.

Authors:  Nabanita Patra; Umasankar De; Tae Hyung Kim; Young Ju Lee; Mee Young Ahn; Nam Deuk Kim; Jung Hyun Yoon; Wahn Soo Choi; Hyung Ryong Moon; Byung Mu Lee; Hyung Sik Kim
Journal:  Biomed Pharmacother       Date:  2013-02-16       Impact factor: 6.529

8.  N-Hydroxy-1,2-disubstituted-1H-benzimidazol-5-yl acrylamides as novel histone deacetylase inhibitors: design, synthesis, SAR studies, and in vivo antitumor activity.

Authors:  Haishan Wang; Niefang Yu; Hongyan Song; Dizhong Chen; Yong Zou; Weiping Deng; Pek Ling Lye; Joyce Chang; Melvin Ng; Eric T Sun; Kanda Sangthongpitag; Xukun Wang; Xiaofeng Wu; Hwee Hoon Khng; Lijuan Fang; Siok Kun Goh; Wai Chung Ong; Zahid Bonday; Walter Stünkel; Anders Poulsen; Michael Entzeroth
Journal:  Bioorg Med Chem Lett       Date:  2009-01-19       Impact factor: 2.823

Review 9.  Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges.

Authors:  Peter Atadja
Journal:  Cancer Lett       Date:  2009-04-02       Impact factor: 8.679

10.  Cell Cycle Arrest and Cytotoxic Effects of SAHA and RG7388 Mediated through p21WAF1/CIP1 and p27KIP1 in Cancer Cells.

Authors:  Umamaheswari Natarajan; Thiagarajan Venkatesan; Vijayaraghavan Radhakrishnan; Shila Samuel; Periannan Rasappan; Appu Rathinavelu
Journal:  Medicina (Kaunas)       Date:  2019-01-29       Impact factor: 2.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.